K2M Obtains Worldwide Exclusive Rights to Revolutionary Injectable Polymer Technology for Treatment of Spinal Disorders

LEESBURG, Va.--(BUSINESS WIRE)--K2M, Inc., a spinal device company developing innovative solutions for the treatment of complex spinal pathologies, today announced that it has entered into an agreement with Promethean Surgical Devices, Inc. (PSD) for the worldwide exclusive rights for all spinal applications of a breakthrough injectable polymer technology which may be used to address numerous spinal disorders.

MORE ON THIS TOPIC